Skip to main content

Cardinal Health Value Stock - Dividend - Research Selection

Cardinal health

ISIN: US14149Y1082 , WKN: 880206

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Cardinal Health, Inc. operates as an integrated healthcare services and products company worldwide. The company\'s Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare, and consumer products to retailers, hospitals, and other healthcare providers. It offers distribution, inventory management, data reporting, new product launch support, and chargeback administration services to pharmaceutical manufacturers; pharmacy and medication therapy management, and patient outcomes services to hospitals, other healthcare providers, and payers; and consulting, patient support, and other services to pharmaceutical manufacturers and healthcare providers. This segment also operates nuclear pharmacies and manufacturing facilities that manufacture, prepare, and deliver radiopharmaceuticals, as well as operates direct-to-patient specialty pharmacies; offers logistics, marketing, and other services; and repackages generic pharmaceuticals and over-the-counter healthcare products. The company\'s Medical segment manufactures and sources medical, surgical, and laboratory products, including cardiovascular and endovascular products; wound care products; surgical drapes, gowns, and apparel; exam and surgical gloves; fluid suction and collection systems; and incontinence, enteral feeding, urology, operating room supply, electrode and needle, and syringe and sharps disposal product lines. It also distributes medical, surgical, and laboratory products to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers, as well as to patients in the home; and assembles and sells sterile and non-sterile procedure kits. In addition, it offers supply chain services to healthcare providers; and post-acute care management, and transition services and software to hospitals, other healthcare providers, and payers. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Cardinal Health: Looking Into The Business Shift

2026-04-21
Cardinal Health is rated Hold as its ongoing business mix shift drives higher margins but is largely priced in at current levels. Read more on CAH stock here.

Here Are 3 Medical Supply Stocks to Consider Amid Rising Prospects

2026-04-20
Here, we highlight three dental supplies stocks, CAH, COO and BDX, which are well positioned to generate wealth for investors amid macro uncertainty.

McKesson Stock: A Compounding Engine Facing Its Critical Test

2026-04-20
McKesson’s net income grew at an average rate of 14.4% over the last three years, yet its earnings per share (EPS) increased by 19.6% annually during that same window. This 5.2% gap represents the additional value management captured for shareholders through a consistent strategy.

10x Genomics Stock Up on Atera Launch, Spatial Biology Scale Enhanced

2026-04-20
TXG stock jumps after unveiling Atera, a next-gen spatial biology platform aiming to scale single-cell analysis and deepen its role in drug discovery and research.

GEHC & DeepHealth Advance AI Breast Cancer Screening Globally

2026-04-20
GE HealthCare expands DeepHealth tie-up to roll out AI-powered mammography tools, improving early breast cancer detection and advancing women's health.

Cardinal Health Targets Community Sites With Advanced Therapies And Partnerships

2026-04-18
Cardinal Health (NYSE:CAH) has released its 2026 Advanced Therapies Report. The report highlights a shift toward administering advanced therapies in community and outpatient settings. It emphasizes expanding patient access, the role of partnerships, and the need for infrastructure development. For Cardinal Health, known for its role in pharmaceutical distribution and healthcare services, this report places advanced therapies at the center of its conversation with providers and stakeholders...

The Dividend Aristocrats Ranked By Quality Scores (April 2026)

2026-04-18
Rank S&P 500 Dividend Aristocrats with my 10-point quality scoring system, valuations & fair value estimates—plus a downloadable spreadsheet.

PacBio Stock Up on New FFPE Workflow Boosting Cancer Sequencing

2026-04-17
PACB stock rises after unveiling a new FFPE workflow with Covaris, boosting HiFi sequencing accuracy and unlocking insights from archived tumor samples.

Should You Continue to Hold Resmed Stock in Your Portfolio?

2026-04-17
RMD's growth strategy, rising device demand and solid finances support momentum, but macro pressures and stiff competition could test its outlook.

Here's Why You Should Retain BDX Stock in Your Portfolio Now

2026-04-16
BD benefits from innovation, strategic deals and strong Q1 results, but reimbursement risks and estimate cuts may temper near-term upside.